Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT06945627
Active, not recruiting Observational

Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections

NCT06945627 · tracked via the Priya Life Science Norway tracker
Sponsor
Sara Poletti
Phase
Observational
Started
2024-05-02
Last updated
2025-05-14

Condition(s) studied

Severe Mental IllnessInflammationViral InfectionsMood DisordersSchizophrenia

Investigational drug(s) / intervention(s)

This research doesn't involve any kind of intervention on the study participants

This research doesn't involve any kind of intervention on the study participants: This research doesn't involve any kind of intervention on the study participants

Study summary

This observational study aims to identify the underlying neurobiological and environmental mechanisms that influence vulnerability or resilience to mental illness in the context of infection and their contribution to severe infective outcomes in people with pre-existing mental illness. The main questions it aims to answer are:

* How do viral infections influence the development of mental illness?
* What neurobiological and environmental factors contribute to influence the development of mental illness following infection?
* How do these factors relate to the severity of infectious illness in people with pre-existing mental disorders?

Researchers will move from large population databases to well-defined, deeply characterised samples to explore the association between infection and subsequent mental health outcomes, and the biological mechanisms behind these changes.

Participants's data has already been collected.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria for the MOOD-MI cohort: * A depressive episode according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria in the course of MDD or BD with: * HDRS score \> 17 * Age 18-65 years; * Signed informed consent, able to understand, speak and write the national language Inclusion Criteria for the COVID-MI cohort: * Having a positive nasopharyngeal swab for COVID-19 in the last 36 months; * Age between 18-25 years; * Signed informed consent, able to understand, speak and write the national language Exclusion Criteria for the MOOD-MI cohort: * History of schizophrenia, schizoaffective disorder, psychosis not otherwise specified; anorexia or bulimia nervosa; * Taking following medications: antipsychotics, anticonvulsants, mood stabilizers; stimulants * Active infection requiring antibiotics therapy; * Immunosuppressed patient or other chronic diseases * Signs of active infection requiring treatment * Use of anti-inflammatory medication on a regular basis for a chronic inflammatory/autoimmune Disorder. Forbidden treatment: corticosteroids, Non Steroidal Anti-inflammatory Drugs, immunosuppressant IV-Ig based treatment * Ongoing fever, infection treated by antibiotics or uncontrolled diabetes type I or II; * Existing cancer or history of cancer in the last 5 years (except skin epidermoid cancer or in-situ cervix cancer); * Known HIV infection or clinically manifest Acquired Immune Deficiency Syndrome (AIDS), Parkinson's or Alzheimer's disease, or any other serious condition likely to interfere e with the conduct of the trial; * Abuse of drugs or alcohol in the past 6 months Exclusion Criteria for the COVID-MI cohort: * Comorbidity for psychotic disorders, verified by SCID-CV; * Current and clinically significant substance use disorder; * Current comorbidity with neurological conditions or severe head trauma, general brain disorder preceding the emergence of PASC, including microhaemorrhages and/or ischaemia occurring during the acute phase of COVID; * Neuropsychological diagnosis of intellectual disability; * Presence of contraindications to blood sampling and/or MRI; * Pregnancy status at the time of recruitment. Other exclusion criteria related to the MRI procedure include: * Aneurysm clip * Implanted neural stimulator * Implanted cardiac pacemaker or auto-defibrillator * Cochlear implant * Ocular foreign body (e.g., metal shavings) * Any implanted device (pumps, infusion devices, etc) * Shrapnel injuries. For epidemiological cohorts (MoBa, TOP, CHS) age between 18 and 65 ya, diagnosis of a severe mental illness (Schizophrenia, Major Depression, Bipolar disorder, anxiety disorders),

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
University of Antwerp Antwerp Belgium
University of Haifa Haifa Israel
IRCCS Ospedale San Raffaele Milan Italy
University of Oslo Oslo Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06945627 on ClinicalTrials.gov ↗ ← All trials in Norway